Event: Thursday, July 30, 2026
Focus: Revenue durability, G7 15-Day adoption, margin follow-through, and whether management raises its 2026 outlook.
Dexcom enters Q2 after a strong start to 2026 and an Investor Day that reset the long-term narrative around broader continuous-glucose-monitoring (CGM) access, product innovation, international expansion, and margin/cash-flow potential. The near-term question is less whether Dexcom can grow—it delivered 15% reported / 12% organic revenue growth in Q1—and more whether its execution is strong enough to support a higher 2026 outlook while investing for the next growth leg.
The stock closed at $75.38 on July 29, up roughly 26.6% since the April 30 Q1 earnings release and 13.3% year to date. That recovery raises the bar: investors will likely want evidence that U.S. demand is improving, G7 15-Day is accelerating conversions and new starts, and Q1’s unusually strong profitability was sustainable rather than simply a favorable first-quarter outcome.
Dexcom’s current 2026 revenue guide is $5.16 billion to $5.25 billion, or approximately 11–13% growth. After generating $1.192 billion in Q1, the company needs $3.968 billion to $4.058 billion across Q2–Q4 to achieve that range.
The Q2 comparison is manageable but not trivial: Q2 2025 revenue grew 15% to $1.157 billion, including 15% U.S. growth and 16% international growth. Investors should look beyond the consolidated headline to determine whether growth is balanced between the U.S. and international markets.
Key revenue questions: - Is U.S. growth reaccelerating from Q1’s 11% rate, or still constrained by relatively modest new reimbursement unlocks? - Can international growth remain a meaningful offset after growing 26% reported and 17% organic in Q1? - Does management retain its view that U.S. and international growth will be relatively balanced for the full year? - Is Stelo tracking to its expected roughly one-point contribution to 2026 growth?
A reiteration of guidance would be acceptable if quarterly execution is solid, but a raise—particularly to revenue—would be a stronger signal given the Q1 start, G7 15-Day momentum, and incremental commercial coverage wins.
G7 15-Day is the central near-term commercial variable. Dexcom expanded the product across all U.S. channels in Q1 and said it expected to convert nearly half of its U.S. installed base by year-end. Management has highlighted better accuracy, longer wear, improved customer satisfaction, and more favorable manufacturing economics.
For Q2, the most important disclosures will be qualitative rather than necessarily numerical:
The product has strategic importance beyond Q2 revenue. A successful conversion supports revenue growth, customer experience, gross-margin expansion, and Dexcom’s competitive positioning before the planned G8 launch in late 2027 or early 2028.
Q1 demonstrated a material earnings inflection:
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue growth | 15% | — |
| Non-GAAP gross margin | 63.5% | 57.5% |
| Non-GAAP operating margin | 22.2% | 13.8% |
| Adjusted EBITDA margin | 30.6% | 22.2% |
| Non-GAAP diluted EPS | $0.56 | $0.32 |
The key debate for Q2 is whether Q1’s margin strength is repeatable. Dexcom retained full-year non-GAAP gross-margin guidance of approximately 63–64%, despite indicating that absent higher fuel and resin costs it likely would have raised the forecast. Management quantified the potential gross-margin risk from those inputs at roughly 50–100 basis points.
At the same time, it raised full-year non-GAAP operating-margin guidance to 23–23.5% and adjusted EBITDA margin guidance to 31–31.5%. That implies confidence in operational leverage even as the company increases R&D, prepares its Ireland manufacturing facility for a Q4 start-up, and invests internationally.
What would be constructive: - Non-GAAP gross margin remains around, or only modestly below, the 63–64% annual framework. - Operating-margin progression is maintained despite planned R&D and facility-ramp spending. - Management narrows or reduces the fuel/resin risk commentary. - Free cash flow stays robust, reinforcing capacity for repurchases and selective M&A.
What would concern investors: - A sharp gross-margin step-down blamed on input costs, mix, or manufacturing execution. - Larger-than-anticipated expense growth. - Commentary suggesting G7 15-Day savings are slower to materialize.
The biggest long-term upside remains U.S. Medicare coverage for people with type 2 diabetes not using insulin. At its May Investor Day, Dexcom said it expects a coverage decision by the end of 2026, with coverage becoming effective around mid-2027 in its planning assumptions.
That timing means CMS coverage should not be embedded as a major 2026 revenue driver. Still, an update on agency engagement, the clinical evidence base, or expected implementation timing could materially affect investor sentiment.
The nearer-term U.S. access catalyst is Prime Therapeutics, which was expected to begin covering Dexcom CGM for all people with diabetes during the summer. Management previously said this should help expand commercial coverage for type 2 non-insulin users to more than 7 million lives by year-end. Q2 may capture little direct revenue contribution depending on implementation timing, but commentary on early physician awareness, prescription activity, and sales-force readiness will matter.
International revenue grew 26% reported in Q1, supported by expanded access in markets such as France and Canada. Dexcom expects to launch G7 15-Day internationally beginning in the second half of 2026, alongside broader Stelo availability and the Flex product rollout in select markets.
Q2 is therefore likely more about validating the underlying international demand trajectory than about major contributions from these new launches. Investors should watch for:
International growth remains a core part of the long-range case, but it also introduces mix and reimbursement-timing variability.
DXCM’s Q2 report is primarily an execution test. Q1 and the May Investor Day established a compelling framework: durable double-digit growth, broader type 2 access, increasing international penetration, a product-driven margin opportunity, and substantial long-term upside from Medicare coverage expansion.
For this quarter, investors should prioritize three indicators: U.S. growth quality, G7 15-Day adoption, and margin durability. A clean result with stable-to-improving guidance would support the view that Dexcom is progressing from a recovery story to a more durable growth-and-cash-flow compounder. Conversely, any evidence that U.S. demand, conversion pacing, or gross-margin strength is weaker than anticipated could be amplified by a stock that has already recovered sharply into the report.